search
Back to results

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

Primary Purpose

Epstein-Barr Virus Infection

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
mRNA-1189
Placebo
Sponsored by
ModernaTX, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Epstein-Barr Virus Infection focused on measuring Infectious mononucleosis, Mononucleosis

Eligibility Criteria

12 Years - 30 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • According to the assessment of the investigator, is in good general health and can comply with study procedures.

Exclusion Criteria:

  • Has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against COVID-19 at least 14 days prior to the screening visit.
  • Has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator).
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has a history of myocarditis, and/or pericarditis.
  • Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection.

Note: Other inclusion and exclusion criteria may apply.

Sites / Locations

  • Medical Affiliated Research InstituteRecruiting
  • Care Access Network
  • Alliance for Multispecialty Research, LLC
  • Smart Cures Clinical ResearchRecruiting
  • Velocity Clinical Research - Banning - PPDSRecruiting
  • Benchmark Research - Colton - HyperCore - PPDSRecruiting
  • Southern California Permanente Medical Group
  • Fomat Medical ResearchRecruiting
  • Center For Clinical Trials LLC -ParamountRecruiting
  • Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS
  • Peninsula Research Associates - Headlands Research - PPDSRecruiting
  • Acclaim Clinical Research
  • California Research Foundation - 4180 Ruffin RdRecruiting
  • Orange County Research CenterRecruiting
  • Research Centers of America - ERG
  • Jacksonville Center For Clinical Research - ERN - PPDSRecruiting
  • Kissimmee Clinical Research Corp
  • University of South Florida
  • iResearch Savannah - CenExel - PPDSRecruiting
  • Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDSRecruiting
  • Clinical Research Atlanta - Headlands - PPDSRecruiting
  • Velocity Clinical ResearchRecruiting
  • Olivo Medical and Wellness CenterRecruiting
  • DM Clinical ResearchRecruiting
  • Velocity Clinical ResearchRecruiting
  • Meridian Clinical Research, LLCRecruiting
  • Alliance for Multispecialty Research, LLC - El Dorado - PPDSRecruiting
  • Johnson County Clin-TrialsRecruiting
  • Alliance for Multispecialty Research LLC, East WichitaRecruiting
  • Michael W Simon MD, PSCRecruiting
  • Velocity Clinical Research - Lafayette - PPDSRecruiting
  • UMass Memorial Medical CenterRecruiting
  • DM Clinical ResearchRecruiting
  • Clinical Research Institute, Inc.Recruiting
  • Sundance Clinical Research - ERN - PPDSRecruiting
  • Meridian Clinical Research (Grand Island, Nebraska)
  • Meridian Clinical Research (Norfolk-Nebraska) - Platinum - PPDSRecruiting
  • Quality Clinical Research - ClinEdge - PPDSRecruiting
  • Meridian Clinical Research-(Omaha Nebraska) - Platinum - PPDSRecruiting
  • Meridian Clinical Research, LLC (Lincoln Nebraska)Recruiting
  • Alliance for Multispecialty Research, LLC
  • Meridian Clinical ResearchRecruiting
  • Velocity Clinical Research
  • Meridian Clinical ResearchRecruiting
  • Lucas ResearchRecruiting
  • Lucas ResearchRecruiting
  • Meridian Clinical ResearchRecruiting
  • Lynn Health Science InstituteRecruiting
  • Velocity Clinical Research
  • Coastal Pediatric AssociatesRecruiting
  • Coastal Carolina Research Center
  • Benchmark Research - Austin - PPDSRecruiting
  • Tekton Research - Texas - Platinum - PPDS
  • ACRC Trials - Hunt - PPDSRecruiting
  • Velocity Clinical Research - Austin - PPDSRecruiting
  • Cedar Health Research - Fort Worth - PPDSRecruiting
  • Benchmark Research - Fort Worth - HyperCore - PPDSRecruiting
  • Ventavia Research GroupRecruiting
  • DM Clinical Research - Texas Center For Drug Development - ERN - PPDSRecruiting
  • DM Clinical Research - Texas Center For Drug Development - ERN - PPDSRecruiting
  • ACRC Trials - Legacy Medical Village Headquarters
  • ACRC TrialsRecruiting
  • Flourish Research - San Antonio - PPDS
  • Victoria Clinical Research GroupRecruiting
  • Tanner ClinicRecruiting
  • Charlottesville Medical Research CenterRecruiting
  • Health Research of Hampton Roads Inc. - Newport NewsRecruiting
  • Alliance for Multispecialty Research, LLC
  • Clinical Research Partners LLC - Richmond - ERN - PPDSRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Part A: mRNA-1189 Dose Level 2

Part A: mRNA-1189 Dose Level 3

Part A: mRNA-1189 Dose Level 4

Part A: Placebo

Part B: mRNA-1189 Dose Level 1

Part B: mRNA-1189 Dose Level 2

Part B: mRNA-1189 Dose Level 3

Part B: mRNA-1189 Dose Level 4

Part B: Placebo

Arm Description

Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.

Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.

Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.

Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.

Outcomes

Primary Outcome Measures

Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Number of Participants with Unsolicited Adverse Events (AEs)
Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine, and AEs of Special Interest (AESIs)
Number of Participants with Laboratory Abnormalities

Secondary Outcome Measures

Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb) and/or Antigen-Specific Binding Antibody (bAb)
Geometric Mean Fold Rise (GMFR) of B-Cell nAb and Antigen-Specific bAb
Number of Participants With Seroconversion of B-Cell nAbs and/or Antigen-Specific bAbs
The number of initially EBV-negative participants with seroconversion from below the lower limit of quantification (LLOQ) to above the LLOQ for EBV-specific (vaccine antigen) binding and nAbs responses and the initially EBV-positive participants with > 2-, 3-, and 4-fold increases in serum binding or nAb titers from baseline (if above LLOQ) will be analyzed.

Full Information

First Posted
December 1, 2021
Last Updated
September 8, 2023
Sponsor
ModernaTX, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05164094
Brief Title
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
Official Title
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 28, 2021 (Actual)
Primary Completion Date
June 18, 2025 (Anticipated)
Study Completion Date
June 18, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ModernaTX, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults and the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to <18-year-old EBV-seronegative healthy adolescents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epstein-Barr Virus Infection
Keywords
Infectious mononucleosis, Mononucleosis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
422 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A: mRNA-1189 Dose Level 2
Arm Type
Experimental
Arm Description
Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
Arm Title
Part A: mRNA-1189 Dose Level 3
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
Arm Title
Part A: mRNA-1189 Dose Level 4
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
Arm Title
Part A: Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
Arm Title
Part B: mRNA-1189 Dose Level 1
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
Arm Title
Part B: mRNA-1189 Dose Level 2
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
Arm Title
Part B: mRNA-1189 Dose Level 3
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
Arm Title
Part B: mRNA-1189 Dose Level 4
Arm Type
Experimental
Arm Description
Participants will receive 3 IM injections of mRNA-1189 at Dose Level 4 on Days 1, 57, and 169.
Arm Title
Part B: Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive 3 IM injection of study drug-matching placebo on Days 1, 57, and 169.
Intervention Type
Biological
Intervention Name(s)
mRNA-1189
Intervention Description
Sterile liquid for injection
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
0.9% sodium chloride (normal saline) injection
Primary Outcome Measure Information:
Title
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time Frame
Up to Day 176 (7-day follow-up after vaccination)
Title
Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame
Up to Day 197 (28-day follow-up after vaccination)
Title
Number of Participants with Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study/Discontinuation of Study Vaccine, and AEs of Special Interest (AESIs)
Time Frame
Day 1 to end of study (EOS) (Day 505)
Title
Number of Participants with Laboratory Abnormalities
Time Frame
Up to Day 176 (7-day follow-up after vaccination)
Secondary Outcome Measure Information:
Title
Geometric Mean Titer (GMT) of B-Cell Neutralizing Antibody (nAb) and/or Antigen-Specific Binding Antibody (bAb)
Time Frame
Days 1, 85, and 197
Title
Geometric Mean Fold Rise (GMFR) of B-Cell nAb and Antigen-Specific bAb
Time Frame
Days 1, 85, and 197
Title
Number of Participants With Seroconversion of B-Cell nAbs and/or Antigen-Specific bAbs
Description
The number of initially EBV-negative participants with seroconversion from below the lower limit of quantification (LLOQ) to above the LLOQ for EBV-specific (vaccine antigen) binding and nAbs responses and the initially EBV-positive participants with > 2-, 3-, and 4-fold increases in serum binding or nAb titers from baseline (if above LLOQ) will be analyzed.
Time Frame
Days 1, 85, and 197

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: According to the assessment of the investigator, is in good general health and can comply with study procedures. Part A: Healthy adult from 18 to 30 years of age (inclusive) at the time of consent (Screening Visit, Day 0). Part B: Healthy adolescent from 12 to <18 years of age at the time of consent (Screening Visit, Day 0). EBV - seronegative as determined by serology at screening. Exclusion Criteria: Has had significant exposure to someone with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or COVID-19 in the past 14 days prior to the screening visit, if the participant has not been fully vaccinated against COVID-19 at least 14 days prior to the screening visit. Has symptomatic acute or chronic illness requiring ongoing medical or surgical care, to include changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). Significant, progressive, unstable or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of study endpoints, assessment of immune response, or adherence to study procedures per investigator judgement. Has a history of myocarditis, and/or pericarditis. Has received or plans to receive any licensed or authorized vaccine, to include COVID-19 vaccines, ≤28 days prior to the first injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after any study vaccine injection, with the exception of licensed influenza vaccines, which may be received more than 14 days before or after any study vaccine injection. Note: Other inclusion and exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Moderna Clinical Trials Support Center
Phone
1-877-777-7187
Email
clinicaltrials@modernatx.com
Facility Information:
Facility Name
Medical Affiliated Research Institute
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Individual Site Status
Recruiting
Facility Name
Care Access Network
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Alliance for Multispecialty Research, LLC
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85281
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Smart Cures Clinical Research
City
Anaheim
State/Province
California
ZIP/Postal Code
92806
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research - Banning - PPDS
City
Banning
State/Province
California
ZIP/Postal Code
92220-3082
Country
United States
Individual Site Status
Recruiting
Facility Name
Benchmark Research - Colton - HyperCore - PPDS
City
Colton
State/Province
California
ZIP/Postal Code
92324
Country
United States
Individual Site Status
Recruiting
Facility Name
Southern California Permanente Medical Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027-5209
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Fomat Medical Research
City
Oxnard
State/Province
California
ZIP/Postal Code
93030
Country
United States
Individual Site Status
Recruiting
Facility Name
Center For Clinical Trials LLC -Paramount
City
Paramount
State/Province
California
ZIP/Postal Code
90723-5459
Country
United States
Individual Site Status
Recruiting
Facility Name
Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS
City
Riverside
State/Province
California
ZIP/Postal Code
92503
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Peninsula Research Associates - Headlands Research - PPDS
City
Rolling Hills
State/Province
California
ZIP/Postal Code
90274
Country
United States
Individual Site Status
Recruiting
Facility Name
Acclaim Clinical Research
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
California Research Foundation - 4180 Ruffin Rd
City
San Diego
State/Province
California
ZIP/Postal Code
92123-1881
Country
United States
Individual Site Status
Recruiting
Facility Name
Orange County Research Center
City
Tustin
State/Province
California
ZIP/Postal Code
92780
Country
United States
Individual Site Status
Recruiting
Facility Name
Research Centers of America - ERG
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Jacksonville Center For Clinical Research - ERN - PPDS
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216-4357
Country
United States
Individual Site Status
Recruiting
Facility Name
Kissimmee Clinical Research Corp
City
Kissimmee
State/Province
Florida
ZIP/Postal Code
34741
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612-3803
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
iResearch Savannah - CenExel - PPDS
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31405
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Research Atlanta - Headlands - PPDS
City
Stockbridge
State/Province
Georgia
ZIP/Postal Code
30281-9054
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research
City
Meridian
State/Province
Idaho
ZIP/Postal Code
83642
Country
United States
Individual Site Status
Recruiting
Facility Name
Olivo Medical and Wellness Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60618-8101
Country
United States
Individual Site Status
Recruiting
Facility Name
DM Clinical Research
City
River Forest
State/Province
Illinois
ZIP/Postal Code
60305
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research
City
Valparaiso
State/Province
Indiana
ZIP/Postal Code
46383
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research, LLC
City
Sioux City
State/Province
Iowa
ZIP/Postal Code
51106
Country
United States
Individual Site Status
Recruiting
Facility Name
Alliance for Multispecialty Research, LLC - El Dorado - PPDS
City
El Dorado
State/Province
Kansas
ZIP/Postal Code
67042-2187
Country
United States
Individual Site Status
Recruiting
Facility Name
Johnson County Clin-Trials
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
Individual Site Status
Recruiting
Facility Name
Alliance for Multispecialty Research LLC, East Wichita
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67207
Country
United States
Individual Site Status
Recruiting
Facility Name
Michael W Simon MD, PSC
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40517-8379
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research - Lafayette - PPDS
City
Lafayette
State/Province
Louisiana
ZIP/Postal Code
70508-5173
Country
United States
Individual Site Status
Recruiting
Facility Name
UMass Memorial Medical Center
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01605
Country
United States
Individual Site Status
Recruiting
Facility Name
DM Clinical Research
City
Southfield
State/Province
Michigan
ZIP/Postal Code
48076
Country
United States
Individual Site Status
Recruiting
Facility Name
Clinical Research Institute, Inc.
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55402
Country
United States
Individual Site Status
Recruiting
Facility Name
Sundance Clinical Research - ERN - PPDS
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research (Grand Island, Nebraska)
City
Grand Island
State/Province
Nebraska
ZIP/Postal Code
68803
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Meridian Clinical Research (Norfolk-Nebraska) - Platinum - PPDS
City
Norfolk
State/Province
Nebraska
ZIP/Postal Code
68701
Country
United States
Individual Site Status
Recruiting
Facility Name
Quality Clinical Research - ClinEdge - PPDS
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68112
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research-(Omaha Nebraska) - Platinum - PPDS
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68134
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research, LLC (Lincoln Nebraska)
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68510
Country
United States
Individual Site Status
Recruiting
Facility Name
Alliance for Multispecialty Research, LLC
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Meridian Clinical Research
City
Binghamton
State/Province
New York
ZIP/Postal Code
13901
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research
City
East Syracuse
State/Province
New York
ZIP/Postal Code
13057
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Meridian Clinical Research
City
Endwell
State/Province
New York
ZIP/Postal Code
13760
Country
United States
Individual Site Status
Recruiting
Facility Name
Lucas Research
City
Morehead City
State/Province
North Carolina
ZIP/Postal Code
28557
Country
United States
Individual Site Status
Recruiting
Facility Name
Lucas Research
City
New Bern
State/Province
North Carolina
ZIP/Postal Code
28562
Country
United States
Individual Site Status
Recruiting
Facility Name
Meridian Clinical Research
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Name
Lynn Health Science Institute
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73112
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research
City
Anderson
State/Province
South Carolina
ZIP/Postal Code
29621
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Coastal Pediatric Associates
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29414-5834
Country
United States
Individual Site Status
Recruiting
Facility Name
Coastal Carolina Research Center
City
North Charleston
State/Province
South Carolina
ZIP/Postal Code
29405
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Benchmark Research - Austin - PPDS
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Individual Site Status
Recruiting
Facility Name
Tekton Research - Texas - Platinum - PPDS
City
Austin
State/Province
Texas
ZIP/Postal Code
78745
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
ACRC Trials - Hunt - PPDS
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75010
Country
United States
Individual Site Status
Recruiting
Facility Name
Velocity Clinical Research - Austin - PPDS
City
Cedar Park
State/Province
Texas
ZIP/Postal Code
78613-3936
Country
United States
Individual Site Status
Recruiting
Facility Name
Cedar Health Research - Fort Worth - PPDS
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Individual Site Status
Recruiting
Facility Name
Benchmark Research - Fort Worth - HyperCore - PPDS
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76135
Country
United States
Individual Site Status
Recruiting
Facility Name
Ventavia Research Group
City
Houston
State/Province
Texas
ZIP/Postal Code
77008
Country
United States
Individual Site Status
Recruiting
Facility Name
DM Clinical Research - Texas Center For Drug Development - ERN - PPDS
City
Houston
State/Province
Texas
ZIP/Postal Code
77065
Country
United States
Individual Site Status
Recruiting
Facility Name
DM Clinical Research - Texas Center For Drug Development - ERN - PPDS
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Individual Site Status
Recruiting
Facility Name
ACRC Trials - Legacy Medical Village Headquarters
City
Plano
State/Province
Texas
ZIP/Postal Code
75024-4174
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
ACRC Trials
City
Plano
State/Province
Texas
ZIP/Postal Code
75024
Country
United States
Individual Site Status
Recruiting
Facility Name
Flourish Research - San Antonio - PPDS
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Victoria Clinical Research Group
City
Victoria
State/Province
Texas
ZIP/Postal Code
77979
Country
United States
Individual Site Status
Recruiting
Facility Name
Tanner Clinic
City
Layton
State/Province
Utah
ZIP/Postal Code
84041
Country
United States
Individual Site Status
Recruiting
Facility Name
Charlottesville Medical Research Center
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22911
Country
United States
Individual Site Status
Recruiting
Facility Name
Health Research of Hampton Roads Inc. - Newport News
City
Newport News
State/Province
Virginia
ZIP/Postal Code
23606-4537
Country
United States
Individual Site Status
Recruiting
Facility Name
Alliance for Multispecialty Research, LLC
City
Norfolk
State/Province
Virginia
ZIP/Postal Code
23502
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
Clinical Research Partners LLC - Richmond - ERN - PPDS
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23226-3787
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-Year-Old Healthy Adolescents and Adults

We'll reach out to this number within 24 hrs